Acute myeloid leukemia (AML)
Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow and is responsible for the largest number of leukemia deaths annually.
Novartis aims to tackle breast cancer with bold science, collaboration, and a passion for transforming patient care. We take a bold approach to our research by including patient populations who are often neglected in clinical trials, identifying new pathways or mutations that may play a role in disease progression, and developing therapies to help extend and improve the lives of patients.
Together with partners, we are committed to reimagining the fight against chagas disease and advocating for an integrated, end-to-end care approach.
Chronic Myeloid Leukemia (CML)
Chronic myeloid leukemia, or CML, is a type of cancer that develops in the blood-forming cells of the bone marrow, in which immature cells build up and eventually invade the blood.
Coronavirus disease (COVID-19)
Novartis has been responding to the coronavirus disease (COVID-19) with safety of associates and patients globally as our primary concern. We have been also contributing to research efforts, supporting communities and ensuring stable supply and price of essential medicines.
Dry eye disease (DED)
Dry eye disease (DED), also known as keratoconjunctivitis sicca, can develop due to tear hyperosmolarity, tear film dysfunction, and lack of adaptation. Prevalence data varies but as many as 5 to 50% of people could be affected globally.
Answer your questions on a type of cholesterol called lipoprotein(a), including how elevated levels can contribute to a cardiovascular disease.
Heart failure is a debilitating and potentially life-threatening condition where the heart cannot pump enough blood around the body, leaving patients fatigued, short of breath, and at risk of sudden cardiac death.
The kidneys play a vital role in keeping us healthy, and often it is only when something goes wrong that we realize just how important our kidneys are. Learn more about kidney disease, including rare kidney diseases, and the impact they have on patients and healthcare systems.
For more than 30 years, Novartis and the Novartis Foundation have been working with partners around the world to eliminate leprosy – and we are committed to going the last mile.
Lung cancer is one of the most common cancers worldwide, accounting for more than 2 million new cases diagnosed each year.
We have been committed to the fight against malaria for the past two decades. Today we are working on the development of the next generation of antimalarials.
Melanoma is the most serious type of skin cancer, and many times, it is caused by damage to the DNA in skin cells.
Migraine is a serious and distinct neurological disease affecting 1 billion people worldwide, and impacting women three times more than men. Migraine involves recurrent attacks of moderate-to-severe head pain associated with nausea, vomiting and sensitivity to light, sound and odors.
Multiple myeloma (MM)
Learn about multiple myeloma and Novartis' commitment to research & development for patients living with this rare cancer.
Multiple sclerosis (MS)
Multiple sclerosis (MS) is a chronic disorder of the central nervous system that disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss. Approximately 2.3 million people worldwide are affected by MS, of which 3 to 5% are estimated to be children.
Neuroendocrine tumors (NETs)
Through the science of targeted therapies, our goal is to reduce the global disease burden and extend the lives of patients with neuroendocrine cancer.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic, and serious blood disorder that comes with a range of mild to severe symptoms. Learn more about the importance of spotting the signs of PNH and the wider impact of the disease.
Prostate cancer is the most frequently diagnosed cancer in more than half of the world's countries. Our goal is to use the science of targeted therapies to reduce the global disease burden, extend the lives of patients, and elevate current standards of care.
Sickle cell disease (SCD)
Novartis is pursuing a comprehensive approach to tackling SCD. We are developing innovative new medicines to treat it and are working to expand access to diagnosis, treatment and care.
At Novartis, we invest in the most promising frontiers of science, the most exciting innovations in the business of medicine, and the most significant healthcare needs.
Benefiting from our continued focus on innovation, Novartis has one of the industry's most competitive pipelines.
List of the treatments we currently offer via our Innovative Medicines division.